Ovid/Graviton announce positive Phase 1 data for OV888/GV101 CCM therapy; Phase 2 expected H2 2024

Ovid Therapeutics Inc.

Phase 1 met primary safety/tolerability objectives: no serious adverse events at any dose.
Headache was most common AE (23%); all mild and resolved within 24 hours.
Target PK achieved: half-life ~12 hours supports once-daily dosing.
Dose-dependent decrease in proinflammatory cytokines IL-17 and IL-21 confirms ROCK2 target engagement.
Phase 2 proof-of-concept study in cerebral cavernous malformations planned for second half 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.